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We report the case of a 54-year-old Caucasian female who presented with a two-year history of persistent hypocalcemia
requiring multiple hospitalizations. Her medical history was significant for HIV diagnosed four years ago. She denied any history
of prior neck surgery or radiation. Her vital signs were stable with an unremarkable physical exam. Pertinent medications
included calcium carbonate, vitamin D3, calcitriol, efavirenz, emtricitabine, tenofovir disoproxil, hydrochlorothiazide, and inhaled
budesonide/formoterol. Laboratory testing showed total calcium of 5.7mg/dL (normal range: 8.4-10.2mg/dL), ionized calcium
of 2.7mg/dL (normal range: 4.5-5.5mg/dL), serum phosphate of 6.3mg/dL (normal range: 2.7-4.5mg/dL), and intact PTH of
7.6 pg/mL (normal range: 15-65 pg/mL). She was diagnosed with primary hypoparathyroidism. Anti-calcium-sensing receptor
antibodies and NALP5 antibodies were tested and found to be negative. During subsequent clinic visits, doses of calcium
supplements and calcitriol were titrated. Last corrected serumcalcium level was 9.18mg/dL. She was subsequently lost to follow-up.
This case gives insight into severe symptomatic hypocalcemia from primary hypoparathyroidism attributed to HIV infection. We
suggest that calcium levels should be closely monitored in patients with HIV infection.
1. Introduction
Endocrine involvement is frequent in HIV infected patients,
although it rarely involves the parathyroid glands [1].
Hypocalcemia is an infrequent phenomenon in HIV infec-
tion and it is mostly attributed to Vitamin D deficiency,
hypoalbuminemia, or pharmacotherapy. We report a rare
case of severe symptomatic hypocalcemia from primary
hypoparathyroidism attributed to HIV infection.
2. Case Presentation
A54-year-old Caucasian female presented to our clinic with a
two-year history of persistent hypocalcemia requiring multi-
ple hospitalizations. Her symptoms included muscle cramps,
tingling and perioral paresthesias. Her medical history was
significant for HIV diagnosed four years ago, gastric bypass
surgery done 15 years ago, hypertension, and COPD. She
denied any history of prior neck surgery or radiation. She
denied any history of hearing loss. She had no family history
of autoimmune disease.
Her vital signs were stable with an unremarkable phys-
ical exam. Chvostek’s and Trousseau’s signs were negative.
Pertinent medications included calcium carbonate, vitamin
D3, calcitriol, atripla (efavirenz/emtricitabine/tenofovir diso-
proxil), hydrochlorothiazide, and inhaled budesonide/for-
moterol.
Laboratory testing showed total calcium of 5.7mg/dL
(normal range: 8.4-10.2mg/dL), serum albumin 3.9mg/dL,
ionized calcium 2.7mg/dL (normal range: 4.5-5.5mg/dL),
serum magnesium 1.7mg/dL (normal range: 1.7-2.7mg/dL),
serum phosphate 6.3mg/dL (normal range: 2.7-4.5mg/dL),
and intact PTH 7.6 pg/mL (normal range: 15-65 pg/mL).
She had normal 25-hydroxy vitamin D 32 ng/mL (normal
range: 30-100ng/mL), 1,25 dihydroxy vitamin D 23 pg/mL
(normal range: 18-72 pg/mL), TSH 1.2𝜇IU/L (normal range:
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Table 1: Clinical course showing laboratory studies and treatment regimen.
Date
Corrected total
calcium (normal
range, 8.4–10.2
mg/dL)
Ionized calcium
(normal range, 4.5-5.5
mg/dL)
Serum phosphate
(normal range,
2.7–4.5 mg/dL)
Medications
11/2012 6.9 3.0 5.9
Calcitriol 0.25 mcg daily
Total elemental calcium 1440 mg daily (as calcium
carbonate 3600 mg daily in divided doses)
Vitamin D 50,000 units weekly
12/2012 7.0 3.5 5.9
Calcitriol 0.25 mcg twice daily
Total elemental calcium 2400 mg daily (as calcium
carbonate 6000 mg daily in divided doses)
Vitamin D 50,000 units weekly
3/2013 7.2 3.5 5.7
Calcitriol 0.25 mcg three times daily
Total elemental calcium 1800 mg daily (as calcium
carbonate 4500 mg daily in divided doses)
Vitamin D 50,000 units weekly
6/2013 7.0 3.2 5.4
Calcitriol 0.5 mcg twice daily
Total elemental calcium 2000 mg daily (as calcium
carbonate 5000 mg daily in divided doses)
Vitamin D 50,000 units weekly
8/2013 7.9 - -
Calcitriol 0.5 mcg three times daily
Total elemental calcium 3600 mg daily (as calcium
carbonate 7500 mg daily and calcium citrate 2850 mg daily
in divided doses)
Vitamin D 50,000 units weekly
11/2013 9.2 4.8 -
Calcitriol 0.5 mcg three times daily
Total elemental calcium 3800 mg daily (as calcium
carbonate 7500 mg daily and calcium citrate 3800 mg daily
in divided doses)
Vitamin D 50,000 units weekly
0.40-4.5𝜇IU/L), and creatinine 0.98mg/dL (normal range:
0.5 -1.1mg/dL). AbsoluteCD4 countwas 629 cells/𝜇L (normal
range: 185-2273 cells/𝜇L) with undetectable HIV-1 RNA viral
load.
She was diagnosed with primary hypoparathyroidism. A
serum sample was tested for anti-calcium sensing receptor
(CaSR) antibodies [2] and NALP5 antibodies [2] to rule
out autoimmune hypoparathyroidism and it was found to
be negative; the CaSR antibody index was 1.09 (normal
range: 0.57-1.38; upper limit of normal, 1.73) and the NALP5
antibody index was 1.12 (normal range: 0.62-1.93; upper limit
of normal, 2.17). During subsequent clinic visits, doses of
calcium supplements and calcitriol were titrated and she was
started onmagnesium oxide. She required calcium carbonate
2500mg three times per day, calcium citrate 1900mg twice
per day, and calcitriol 0.5 mcg three times per day (Table 1).
Her last corrected serum calcium level was 9.18mg/dL. She
was considered for treatment with recombinant human PTH
but subsequently she was lost to follow-up.
3. Discussion
Hypocalcemia is defined as low albumin corrected total
serum calcium or low ionized serum calcium levels. It
is a relatively common condition. Broadly, the causes of
hypocalcemia are divided into disorders associated with low
or high PTH levels, drugs, and hypomagnesemia [3], as
shown in Table 2.
Increased prevalence of hypocalcemia has been reported
in HIV positive individuals, but it was mostly related to
vitamin D deficiency [4]. A retrospective review reported
greater frequency of parathyroid hyperplasia in autopsy
specimens of HIV infected African American patients, which
could be result of high prevalence of vitamin D deficiency in
HIV infected patients [5].
Other causes of hypocalcemia in HIV infected patients
are attributed to hypoalbuminemia [6], medications like
foscarnet [7] and Fanconi’s syndrome related to antiretroviral
medications [8]. Tenofovir can rarely cause hypocalcemia as
part of Fanconi’s syndrome, along with hypophosphatemia
and normal or slightly elevated PTH levels [9].
Our patient had hypocalcemia, hyperphosphatemia with
low PTH levels, consistent with primary hypoparathy-
roidism. With the absence of neck surgery and an unlikely
autoimmune etiology (negative antibody testing, late onset,
absence of family history, hearing loss, and associated condi-
tions), HIV infection was considered as the principal etiology
causing hypoparathyroidism leading to hypocalcemia. This
has been very rarely reported in literature [10].
The cause of hypoparathyroidism in HIV infected indi-
viduals is thought to be related to impaired parathyroid
hormone release and altered parathyroid function [11, 12].
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Table 2: Pathogenesis and differential diagnosis of hypocalcemia.
Hypocalcemia
associated with Disorders
Low PTH
Abnormal PTH synthesis; Abnormal parathyroid gland development; Post-surgical
hypoparathyroidism; Autoimmune polyglandular syndrome type 1;
Activating mutations of the calcium-sensing receptor; Infiltration of parathyroid
gland; Radiation-induced hypoparathyroidism; HIV infection; Hungry bone
syndrome
High PTH
Vitamin D deficiency or resistance; PTH resistance
(pseudohypoparathyroidism); Loss of calcium in circulation (tumor lysis syndrome,
acute pancreatitis, sepsis, osteoblastic metastases, hyperphosphatemia); Renal
disease
Drugs
Inhibitors of bone resorption (bisphosphonates, calcitonin, denosumab);
Cinacalcet; Calcium chelators (EDTA, citrate, phosphate); Foscarnet; Phenytoin;
Fluoride poisoning
Disorders of
magnesium
metabolism
Hypomagnesemia causing functional hypoparathyroidism
Mechanisms explaining hypoparathyroidism inHIV infected
patients are not well described. There is suggestion of expres-
sion of a CD4 like molecule by the parathyroid cells making
them a potential target of HIV, leading to impaired PTH
secretion [13].
Further, our patient was unique and challenging to man-
age due to requirement of high doses of calcium, calcitriol,
and Vitamin D. It may be in part due to previous history
of gastric bypass surgery which may impair calcium and
Vitamin D absorption.
4. Conclusion
Although rare, primary hypoparathyroidism should be con-
sidered in the differential diagnosis of hypocalcemia in HIV
infected patients. We suggest that calcium levels, PTH levels,
and 25(OH) vitamin D levels should be monitored regularly
in those patients.
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